Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2022 | $10.00 | Buy | Jefferies |
| 11/23/2021 | Neutral → Outperform | SMBC Nikko | |
| 8/6/2021 | $18.00 → $16.00 | Outperform | Oppenheimer |
| 8/6/2021 | $27.00 → $25.00 | Buy | HC Wainwright & Co. |
Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc. Paris, France – April 26, 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Sanofi's proposed acquisition of Provention Bio, Inc. (("Provention Bio", NASDAQ:PRVB) has expired. On March 24, 2023, Sanofi commenced a cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Provention Bio (the "Shares"), for $25.00 per Share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law. As a result of the expiration of
RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, Marc
RED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a new non-executive employee to purchase an aggregate of 10,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employee entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of directors.
Submission status for PROVENTION BIO INC's drug TZIELD (ORIG-1) with active ingredient TEPLIZUMAB-MZWV has changed to 'Approval' on 11/17/2022. Application Category: BLA, Application Number: 761183, Application Classification:
15-12G - Provention Bio, Inc. (0001695357) (Filer)
EFFECT - Provention Bio, Inc. (0001695357) (Filer)
EFFECT - Provention Bio, Inc. (0001695357) (Filer)
Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Sanofi's proposed acquisition of Provention Bio, Inc. (("Provention Bio", NASDAQ:PRVB) has expired.
Sanofi SA (NASDAQ:SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC) regarding the acquisition of Provention Bio Inc (NASDAQ:PRVB). Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion. The agency, it added, needed more time to look at the deal and “information recently provided to them,” Sanofi said in an SEC filing. In its disclosure, Sanofi added that “withdrawing and refiling premerger notifications is a standard procedure to provide additional time for antitrust review of certain transac
Sanofi announced today that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Sanofi’s pending acquisition of Provention Bio, Inc. As previously announced on March 24, 2023, Sanofi commenced a cash tender offer to purchase all outstanding shares of common stock of Provention Bio, Inc. (the “Shares”), for $25.00 per Share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law. Sanofi has elected to withdraw and refile its Premerger Notification and Report Form, which was initially filed on March 24, 2023,
RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors. Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, Inc., AbbVie, Abbott Laboratories, and G.D. Searle and Co. prior to the latter's merger with Pharmacia & Upjohn and subsequent acquisition by Pfizer. "
RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development. Dr. Hillson bolsters the Company's clinical development leadership group with significant experience in all phases of clinical development across various autoimmune disorders, including systemic lupus erythematosus, which is the lead target indication for PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B.
RED BANK, N.J., Nov. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development. Dr. Sanjuan further strengthens the Company's internal expertise in the core areas of immunomodulatory therapy, translational medicine and autoimmune disease. "As we continue to grow as an organization pioneering early interception and prevention of debilitating and life-threatening autoimm
Jefferies initiated coverage of Provention Bio with a rating of Buy and set a new price target of $10.00
SMBC Nikko upgraded Provention Bio from Neutral to Outperform
Oppenheimer reiterated coverage of Provention Bio with a rating of Outperform and set a new price target of $16.00 from $18.00 previously
SC 13G/A - Provention Bio, Inc. (0001695357) (Subject)
SC 13G/A - Provention Bio, Inc. (0001695357) (Subject)
SC 13G - Provention Bio, Inc. (0001695357) (Subject)
4 - Provention Bio, Inc. (0001695357) (Issuer)
4 - Provention Bio, Inc. (0001695357) (Issuer)
4 - Provention Bio, Inc. (0001695357) (Issuer)
RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, Marc
RED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (intern
TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune diseaseIn a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by 25 months, or approximately 2 years, compared to placeboStage 3 T1D is associated with significant health risks, including diabetic ketoacidosis, which can be life threateningPatients who progress to Stage 3 T1D eventually require insulin injections for lifeInvestor Conference call at 8:00am ET tomorrowRED BANK, N.J., Nov. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced